American Association for Cancer Research
00085472can201504-sup-242715_2_supp_6812870_qm405m.pdf (39.97 MB)

Supplementary Data from CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia

Download (39.97 MB)
journal contribution
posted on 2023-03-31, 04:06 authored by Husheng Ding, Nicole D. Vincelette, Cordelia D. McGehee, Mira A. Kohorst, Brian D. Koh, Annapoorna Venkatachalam, X. Wei Meng, Paula A. Schneider, Karen S. Flatten, Kevin L. Peterson, Cristina Correia, Sun-Hee Lee, Mrinal Patnaik, Jonathan A. Webster, Gabriel Ghiaur, B. Douglas Smith, Judith E. Karp, Keith W. Pratz, Hu Li, Larry M. Karnitz, Scott H. Kaufmann

Supplementary methods, three supplementary tables and 16 supplementary figures





Although inhibitors of the kinases CHK1, ATR, and WEE1 are undergoing clinical testing, it remains unclear how these three classes of agents kill susceptible cells and whether they utilize the same cytotoxic mechanism. Here we observed that CHK1 inhibition induces apoptosis in a subset of acute leukemia cell lines in vitro, including TP53-null acute myeloid leukemia (AML) and BCR/ABL–positive acute lymphoid leukemia (ALL), and inhibits leukemic colony formation in clinical AML samples ex vivo. In further studies, downregulation or inhibition of CHK1 triggered signaling in sensitive human acute leukemia cell lines that involved CDK2 activation followed by AP1-dependent TNF transactivation, TNFα production, and engagement of a TNFR1- and BID-dependent apoptotic pathway. AML lines that were intrinsically resistant to CHK1 inhibition exhibited high CHK1 expression and were sensitized by CHK1 downregulation. Signaling through this same CDK2–AP1–TNF cytotoxic pathway was also initiated by ATR or WEE1 inhibitors in vitro and during CHK1 inhibitor treatment of AML xenografts in vivo. Collectively, these observations not only identify new contributors to the antileukemic cell action of CHK1, ATR, and WEE1 inhibitors, but also delineate a previously undescribed pathway leading from aberrant CDK2 activation to death ligand–induced killing that can potentially be exploited for acute leukemia treatment. This study demonstrates that replication checkpoint inhibitors can kill AML cells through a pathway involving AP1-mediated TNF gene activation and subsequent TP53-independent, TNFα-induced apoptosis, which can potentially be exploited clinically.

Usage metrics

    Cancer Research





    Ref. manager